Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences

2/20/25 7:30:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TNGX alert in real time by email

BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Feb. 20, 2025-- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Tango Therapeutics management is scheduled to participate in three upcoming investment bank conferences. The B Riley Precision Oncology & Radiopharma Conference will be held in New York, NY in late February. The Leerink Global Healthcare Conference and Barclays 27^th Annual Global Healthcare Conference will be held in Miami, FL in March.

B Riley Precision Oncology & Radiopharma Conference

Panel participation on Friday, February 28 at 9:00-10:00 AM ET
Panel title "Pushing Tumors Over the Edge with Synthetic Lethality"

Leerink Global Healthcare Conference

Fireside chat on Wednesday, March 12 at 2:20-2:50 PM ET
Webcast link HERE

Barclays 27^th Annual Global Healthcare Conference

Available for 1x1 meetings on Thursday, March 13

The live webcast for each event will be available under the "Events & Presentations" tab on the "Investors" page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

If you are interested in arranging a 1x1 meeting with management, please contact your conference representative.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.

Investor Contact:

Daniella Beckman

Chief Financial Officer, Tango Therapeutics

[email protected]

Media Contact:

Daniella Beckman

Chief Financial Officer, Tango Therapeutics

[email protected]

Source: Tango Therapeutics, Inc.

Get the next $TNGX alert in real time by email

Recent Analyst Ratings for

$TNGX

Date	Price Target	Rating	Analyst
7/17/2024	$19.00	Buy	Jefferies
4/4/2024		Overweight	Cantor Fitzgerald
2/12/2024	$18.00	Overweight	Piper Sandler
12/8/2023	$16.00	Buy	B. Riley Securities
10/20/2022	$10.00	Neutral → Buy	H.C. Wainwright
9/20/2021	$25.00	Outperform	SVB Leerink
9/7/2021	$12.00	Outperform	Wedbush
9/7/2021	$20.00	Outperform	Wedbush

More analyst ratings

Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences

Chat with this insight

Recent Analyst Ratings for
$TNGX

$TNGX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

General Counsel Barry Douglas sold $16,369 worth of shares (5,330 units at $3.07), decreasing direct ownership by 7% to 66,014 units (SEC Form 4)

Chief Financial Officer Beckman Daniella sold $25,282 worth of shares (8,232 units at $3.07), decreasing direct ownership by 5% to 150,284 units (SEC Form 4)

Officer Crystal Adam sold $43,866 worth of shares (14,283 units at $3.07), decreasing direct ownership by 8% to 158,210 units (SEC Form 4)

$TNGX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Jefferies initiated coverage on Tango Therapeutics with a new price target

Cantor Fitzgerald initiated coverage on Tango Therapeutics

Piper Sandler initiated coverage on Tango Therapeutics with a new price target

$TNGX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Rothenberg Mace bought $74,000 worth of shares (20,000 units at $3.70), increasing direct ownership by 178% to 31,250 units (SEC Form 4)

Boxer Capital, Llc bought $8,722,500 worth of shares (1,250,000 units at $6.98) (SEC Form 4) (Amendment)

Boxer Capital, Llc bought $8,722,500 worth of shares (1,250,000 units at $6.98) (SEC Form 4)

$TNGX
Press Releases

Fastest customizable press release news feed in the world